REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients

被引：0

作者：

Lombardi, G. ^{[1
]}

De Salvo, G. L. ^{[2
]}

Brandes, A. A. ^{[3
]}

Eoli, M. ^{[4
]}

Ruda, R. ^{[5
,6
]}

Faedi, M. ^{[7
]}

Lolli, I. ^{[8
]}

Pace, A. ^{[9
]}

Rizzato, S. ^{[10
]}

Germano, D. ^{[11
]}

Pasqualetti, F. ^{[12
]}

Farina, M. ^{[2
]}

Magni, G. ^{[2
]}

Pambuku, A. ^{[1
]}

Bergo, E. ^{[1
]}

Cabrini, G. ^{[13
]}

Indraccolo, S. ^{[14
]}

Gardiman, M. P. ^{[15
]}

Zagonel, V. ^{[1
]}

机构：

[1] Veneto Inst Oncol IOV IRCCS, Med Oncol 1, Dept Clin & Expt Oncol, Padua, Italy

[2] Veneto Inst Oncol IOV IRCCS, Clin Trials & Biostat Unit, Padua, Italy

[3] Azienda USL IRCCS Sci Neurol, Med Oncol Dept, Bologna, Italy

[4] Carlo Besta Inst, Mol Neuroncol Unit, Milan, Italy

[5] Univ Turin, Dept Neurooncol, Turin, Italy

[6] City Hlth & Sci Hosp, Turin, Italy

[7] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Med Oncol Unit, Meldola, Italy

[8] IRCCS Saverio Bellis, Med Oncol Unit, Castellana Grotte, Italy

[9] Ist Nazl Tumori Regina Elena, Neuroncol Unit, Rome, Italy

[10] Azienda Sanit Univ Integrata Udine, Med Oncol Unit, Udine, Italy

[11] Azienda Osped G Rummo, Med Oncol Unit, Benevento, Italy

[12] Azienda Osped Univ S Chiara, Radiotherapy Unit, Pisa, Italy

[13] Azienda Osped Univ Integrata Verona, Mol Pathol Unit, Verona, Italy

[14] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy

[15] Azienda Osped Univ Padova, Pathol Dept, Padua, Italy

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA16

引用

页数：1

共 50 条

[1] REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).
Lombardi, Giuseppe
De Salvo, Gian Luca
Eoli, Marica
Brandes, Alba Ariela
Ruda, Roberta
Faedi, Marina
Pace, Andrea
Lolli, Ivan
Pasqualetti, Francesco
Rizzato, Simona
Germano, Domenico
Maiello, Evaristo
Indraccolo, Stefano
Cabrini, Giulio
Gardiman, Marina Paola
Zagonel, Vittorina
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).
Lombardi, Giuseppe
De Salvo, Gian Luca
Ruda, Roberta
Franceschi, Enrico
Eoli, Marica
Faedi, Marina
Pace, Andrea
Lolli, Ivan
Rizzato, Simona
Germano, Domenico
Pasqualetti, Francesco
Farina, Miriam
Magni, Giovanna
Bellu, Luisa
Pambuku, Ardi
Bergo, Eleonora
Indraccolo, Stefano
Gardiman, Marina Paola
Soffietti, Riccardo
Zagonel, Vittorina
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] UPDATED RESULTS OF REGOMA: A RANDOMIZED, MULTICENTER, CONTROLLED OPEN-LABEL PHASE II CLINICAL TRIAL EVALUATING REGORAFENIB IN RELAPSED GLIOBLASTOMA <GBM> PATIENTS <PTS>
Lombardi, G.
de Salvo, G.
Ruda, R.
Franceschi, E.
Eoli, M.
Faedi, M.
Pace, A.
Lolli, I.
Rizzato, S.
Germano, D.
Pasqualetti, F.
Farina, M.
Magni, G.
Bellu, L.
Caccese, M.
Pambuku, A.
Bergo, E.
Indraccolo, S.
Gardiman, M.
Soffietti, R.
Zagonel, V.
NEURO-ONCOLOGY, 2018, 20 : 219 - 219
[4] Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
Lombardi, Giuseppe
De Salvo, Gian Luca
Brandes, Alba Ariela
Eoli, Marica
Ruda, Roberta
Faedi, Marina
Lolli, Ivan
Pace, Andrea
Daniele, Bruno
Pasqualetti, Francesco
Rizzato, Simona
Bellu, Luisa
Pambuku, Ardi
Farina, Miriam
Magni, Giovanna
Indraccolo, Stefano
Gardiman, Marina Paola
Soffietti, Riccardo
Zagonel, Vittorina
LANCET ONCOLOGY, 2019, 20 (01) : 110 - 119
[5] HEALTH-RELATED QUALITY OF LIFE (HRQOL) EVALUATION IN THE REGOMA TRIAL: A RANDOMIZED, PHASE II CLINICAL TRIAL ANALYZING REGORAFENIB ACTIVITY IN RELAPSED GLIOBLASTOMA PATIENTS
Lombardi, G.
Del Bianco, P.
Brandes, A.
Eoli, M.
Ruda, R.
Ibrahim, T.
Lolli, I.
Pace, A.
Daniele, B.
Pasqualetti, F.
Rizzato, S.
Bergo, E.
Caccese, M.
Padovan, M.
Soffietti, R.
De Salvo, G.
Zagonel, V.
NEURO-ONCOLOGY, 2019, 21 : 14 - 14
[6] Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients
Lombardi, G.
Del Bianco, P.
Brandes, A. A.
Eoli, M.
Ruda, R.
Ibrahim, T.
Lolli, I. R.
Pace, A.
Daniele, B.
Pasqualetti, F.
Rizzato, S.
Bergo, E.
Caccese, M.
Padovan, M.
Soffietti, R.
De Salvo, G. L.
Zagonel, V.
ANNALS OF ONCOLOGY, 2019, 30
[7] Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.
Lombardi, Giuseppe
Del Bianco, Paola
Brandes, Alba Ariela
Eoli, Marica
Ruda, Roberta
Ibrahim, Toni
Lolli, Ivan
Pace, Andrea
Daniele, Bruno
Pasqualetti, Francesco
Rizzato, Simona
Bergo, Eleonora
Caccese, Mario
Magni, Giovanna
Soffietti, Riccardo
De Salvo, Gian Luca
Zagonel, Vittorina
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Phillips, Tycel J.
Matasar, Matthew
Eyre, Toby A.
Gine, Eva
De L'Etang, Audrey Filezac
Byrne, Ben
Lundberg, Linda
Padovani, Alejandra
Boetsch, Christophe
Bottos, Alessia
Qayum, Naseer
BLOOD, 2023, 142
[9] GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Phillips, Tycel
Matasar, Matthew
Eyre, Toby A.
Gine, Eva
de L'Etang, Audrey Filezac
Byrne, Ben
Lundberg, Linda
Padovani, Alejandra
Boetsch, Christophe
Bottos, Alessia
Qayum, Naseer
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S515 - S515
[10] A Phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
Jones, R. L.
Bendell, J. C.
Smith, D. C.
Deifenbach, K.
Lettieri, J.
Boix, O.
Lockhart, A. C.
O'Bryant, C. L.
Moore, K. N.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S336 - S337

← 1 2 3 4 5 →